TELA Bio, Inc. (NASDAQ:TELA) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Tela Bio Inc. (TELA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AIGH Investment Partners Orin Hirschman | 2,469,373 | $6,247,513 | +50% | 1.76% |
| 2. | OrbiMed Advisors Samuel Isaly | 2,161,185 | $5,467,798 | -13% | 0.09% |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 1,915,126 | $4,845,269 | -22% | 0.24% |
| 4. | SilverArc Capital Devesh Gandhi | 1,124,928 | $2,846,068 | +13% | 0.63% |
| 5. | Stonepine Capital Timothy P. Lynch | 1,110,000 | $2,808,300 | +78% | 1.77% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.25 | 64,444 | Officer | 155,388 | 2024-10-24 | Filing | |
| $2.25 | 22,222 | Officer | 91,082 | 2024-10-24 | Filing | |
| $2.25 | 88,888 | Officer, Director | 458,897 | 2024-10-24 | Filing | |
| $2.25 | 6,666 | Officer | 57,279 | 2024-10-24 | Filing | |
| $8.01 | 5,000 | 3,610,709 | 2022-07-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.54 | 36,600 | Large Shareholder | 2,407,242 | 2024-07-02 | Filing | |
| $4.68 | 13,700 | Large Shareholder | 2,443,842 | 2024-07-01 | Filing | |
| $4.74 | 378,000 | Large Shareholder | 2,457,542 | 2024-06-28 | Filing | |
| $9.41 | 27,700 | Large Shareholder | 2,835,542 | 2023-04-21 | Filing | |
| $9.43 | 28,300 | Large Shareholder | 2,863,242 | 2023-04-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,110,709 | $27,212,894 | 6.73% | |
| 2. | 2,554,641 | $16,911,723 | 1.36% | |
| 3. | 1,078,056 | $7,136,730 | 0% | |
| 4. | 998,853 | $6,612,407 | 0% | |
| 5. | 712,300 | $4,715,426 | 0.01% |
News See All
TELA Bio, Inc. (NASDAQ:TELA) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarter 2024 Earnings Conference Call. [Operator Instructions].
TELA Bio, Inc. (NASDAQ:TELA) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call Transcript
TELA Bio, Inc. misses on earnings expectations. Reported EPS is $-0.53 EPS, expectations were $-0.44.
5 Oversold Healthcare Stocks To Buy Right Now
In this article, we will be taking a look at 5 oversold healthcare stocks to buy right now.
TELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by, and welcome to the TELA Bio Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
TELA Bio, Inc. (NASDAQ:TELA) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode.
TELA Bio, Inc. (NASDAQ:TELA) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TELA Bio, Inc. (NASDAQ:TELA) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
10 Best Healthcare Stocks to Buy According to Matthew Halbower's Pentwater Capital Management
In this article, we discuss the 10 best healthcare stocks to buy according to Matthew Halbower's Pentwater Capital Management.